Drug data last refreshed 11h ago · AI intelligence enriched 4d ago
ALLEGRA ALLERGY (fexofenadine hydrochloride) is a non-sedating H1-receptor antagonist oral tablet approved for allergic rhinitis and chronic urticaria. It works by blocking histamine receptors to reduce allergy symptoms without crossing the blood-brain barrier, minimizing sedation. The drug is a selective peripheral antihistamine used as first-line therapy for mild-to-moderate allergic conditions.
LOE-approaching lifecycle suggests brand team focus is on lifecycle extension, generic defense, and market share stabilization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition
Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions
Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
Worked on ALLEGRA ALLERGY at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ALLEGRA in a LOE-approaching environment offers exposure to defensive commercial strategy, generic competition management, and market access negotiation—critical competencies in mature markets. Team roles emphasize managed care partnerships, payer relationships, and brand loyalty initiatives rather than market expansion or clinical development.